SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a number one precision medication company alive to on the invention, development and commercialization of clinically differentiated, excessive-label healthcare choices for transplant sufferers and caregivers, this day announced the pricing of an underwritten public providing of 1,923,077 shares of its total inventory at a public providing label of $91.00 per half. The atrocious proceeds to CareDx from this providing, sooner than deducting underwriting reductions and commissions and providing prices, are anticipated to be $175,000,007. As effectively as, CareDx has granted the underwriters a 30 day chance to desire up to 288,461 extra shares of its total inventory equipped within the public providing on the a similar terms and prerequisites. The providing is anticipated to discontinuance on or about January 25, 2021, subject to the pride of historical closing prerequisites.
CareDx intends to make exercise of the gain proceeds from this providing for working capital and total company capabilities.
Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint e book-working managers for the providing. Raymond James & Mates, Inc.; BTIG, LLC; Craig-Hallum Capital Team LLC and H.C. Wainwright & Co., LLC are acting as co-managers for the providing.
The public providing will be made pursuant to a shelf registration assertion on Invent S-3ASR (File No. 333-239049) beforehand filed with the Securities and Substitute Commission (the “SEC”) on June 9, 2020, which modified into efficient straight upon filing pursuant to SEC principles. The securities may perhaps well perchance be equipped easiest by manner of a prospectus. A preliminary prospectus supplement and the accompanying prospectus referring to to and describing the terms of the providing fill been filed with the SEC and are readily accessible on the SEC’s net page at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when readily accessible, copies of the final prospectus supplement and the accompanying prospectus referring to to the providing may perhaps well perchance be obtained from Goldman Sachs & Co. LLC, Consideration: Prospectus Department, 200 West Avenue, Original York, NY 10282, by electronic mail at prospectus-the ny@the ny.electronic mail.gs.com or by cellular phone at (866) 471-2526; or Jefferies LLC, Consideration: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Flooring, Original York, NY 10022, by electronic mail at email@example.com or by cellular phone at (877) 821-7388.
This press release does no longer constitute an provide to sell or the solicitation of an provide to clutch, nor shall there be any sale of these securities in any convey or jurisdiction in which such provide, solicitation or sale may perhaps well perchance be unlawful sooner than the registration or qualification below the securities regulations of the kind of convey or jurisdiction.
CareDx, Inc., headquartered in South San Francisco, California, is a number one precision medication choices company alive to on the invention, development and commercialization of clinically differentiated, excessive-label healthcare choices for transplant sufferers and caregivers. CareDx provides products, discovering out companies and products and digital healthcare choices alongside the pre- and post-transplant patient trot, and is the leading provider of genomics-based mostly data for transplant sufferers.
Forward Attempting Statements
This press release entails ahead-looking statements interior the meaning of the Non-public Securities Litigation Reform Act of 1995, as amended, including statements referring to to the underwritten public providing and the anticipated deadline thereof and the amount and exercise of proceeds anticipated from the providing. These ahead-looking statements are based mostly upon data that is for the time being readily accessible to CareDx and its recent expectations, focus on easiest as of the date hereof, and are subject to varied dangers and uncertainties, including dangers connected to market prerequisites and the pride of historical closing prerequisites connected to the proposed public providing, as effectively as total economic and market factors, amongst others discussed in CareDx’s filings with the SEC, including the Annual Suppose on Invent 10-K for the fiscal year ended December 31, 2019 filed by CareDx with the SEC on February 28, 2020 and the periodic reports that CareDx has subsequently filed with the SEC, and the preliminary prospectus supplement connected to the proposed providing filed with the SEC on or relating to the date hereof. Any of these may perhaps well even fair cause CareDx’s accurate outcomes, efficiency or achievements to differ materially and adversely from these anticipated or implied by CareDx’s ahead-looking statements. CareDx expressly disclaims any obligation, except as required by law, or enterprise to replace or revise the kind of ahead-looking statements.